A drug that lets you sleep without tomorrow's fog
In Singapore this September, the ancient human struggle with sleeplessness found a new chapter at the World Sleep Congress, where a Chinese pharmaceutical company presented evidence that a novel drug may offer relief without the burdens that have long shadowed sleep medicine. Fazamorexant works not by forcing the mind into unconsciousness, but by quieting the brain's own wakefulness signals — a distinction that speaks to a broader shift in how science understands rest. The trial results, drawn from over a thousand patients, suggest both efficacy and a cleaner exit from the drug, raising quiet hope for the millions who lie awake wondering if medicine can finally meet them where they are.
- Insomnia affects hundreds of millions globally, and existing treatments carry well-known costs — grogginess, dependency, and the cruel rebound of sleeplessness when patients try to stop.
- Fazamorexant's Phase III trial data, presented before the world's leading sleep researchers, showed faster sleep onset, better sleep efficiency, and fewer nighttime awakenings than competing drugs in its class.
- Crucially, patients who discontinued the drug experienced neither rebound insomnia nor withdrawal symptoms — a finding that directly addresses one of the field's most persistent clinical anxieties.
- Its fast-acting, short-lived profile opens the door to flexible dosing, including a potential middle-of-the-night second dose for patients whose struggle is staying asleep rather than falling asleep.
- Stanford's Emmanuel Mignot signaled interest in further collaboration, and Yangtze River Pharmaceutical has filed for accelerated regulatory review in China, pressing to move from trial data to patient access.
At the World Sleep Congress in Singapore this September, Yangtze River Pharmaceutical Group stepped onto the global stage with Phase III trial results for Fazamorexant — a drug designed to help people both fall asleep and stay asleep, without the heavy sedation that has defined older treatments. The study enrolled 1,034 adults with insomnia in a rigorous placebo-controlled design, and the findings were presented by Dr. Zhu Wenjun of Peking University People's Hospital.
Fazamorexant belongs to a class called dual orexin receptor antagonists, or DORAs, which work by blocking the brain chemicals that sustain wakefulness rather than chemically suppressing the nervous system. The trial showed patients fell asleep faster, slept more efficiently, and woke less during the night — and the improvements compared favorably to published data from competing drugs already on the market. When patients stopped taking Fazamorexant, they experienced no rebound insomnia and no withdrawal symptoms, addressing a concern that has long complicated sleep medication use.
Professor Han Fang of Peking University noted a practical dimension: because the drug acts quickly and clears the body relatively fast, it could be dosed flexibly — once at bedtime for those who struggle to fall asleep, or potentially twice in a single night for those whose problem is staying asleep, without risking next-day drowsiness. The presentation drew the attention of Emmanuel Mignot, director of Stanford University's Center for Sleep and Circadian Sciences, who expressed interest in further trials.
Yangtze River Pharmaceutical has submitted a new drug application to China's National Medical Products Administration and is seeking accelerated review. If approved, Fazamorexant would mark a meaningful moment for Chinese pharmaceutical innovation — a homegrown treatment earning recognition at the highest levels of global medicine, with the potential to reach patients who have long run out of good options.
In Singapore this September, researchers gathered for the World Sleep Congress to hear about a drug that might change how millions of people treat insomnia. Yangtze River Pharmaceutical Group, a Chinese manufacturer, presented the first global results from a Phase III trial of Fazamorexant, a medication designed to help people fall asleep and stay asleep without the grogginess that comes with older treatments.
The trial enrolled 1,034 adults with insomnia in a rigorous, multi-center study where some patients received the drug and others received a placebo, with neither group knowing which they got. Fazamorexant belongs to a class of drugs called dual orexin receptor antagonists, or DORAs—a relatively newer approach to sleep medicine that works by blocking brain chemicals that keep you awake rather than sedating you into unconsciousness. The results showed the drug worked quickly and safely, with patients falling asleep faster, sleeping more efficiently, and waking less often during the night.
What set Fazamorexant apart, according to the trial data presented by Dr. Zhu Wenjun of Peking University People's Hospital, was how it performed on these key measures compared to other DORAs already on the market. The improvements in sleep efficiency and reduced time to fall asleep were notably larger than what published trials of competing drugs had shown. Equally important, patients who stopped taking the drug did not experience rebound insomnia—that frustrating return of sleeplessness that sometimes happens when people discontinue sleep medications—nor did they suffer withdrawal symptoms.
Professor Han Fang of Peking University, a former leader of the World Association of Sleep Medicine, highlighted a practical advantage during the conference presentation. Because Fazamorexant acts quickly and leaves the body relatively fast, it could be dosed flexibly. For people who struggle to fall asleep, a single dose at bedtime works. But for those whose problem is staying asleep through the night, doctors might eventually try giving the drug twice—once at bedtime and again in the middle of the night—without worrying about daytime drowsiness the next morning. This kind of tailored approach could help different patients with different sleep problems.
The presentation drew interest from prominent sleep researchers worldwide. Emmanuel Mignot, a member of the United States National Academy of Sciences and director of Stanford University's Center for Sleep and Circadian Sciences, indicated he wanted to explore further trials with the drug. The World Sleep Congress, held annually in different cities, is the highest-level academic gathering in sleep medicine, drawing top experts and scholars from around the globe.
Yangtze River Pharmaceutical has already submitted a new drug application to China's National Medical Products Administration, seeking approval to bring Fazamorexant to market. The company is pushing for accelerated review, hoping to move quickly from the laboratory to patients' medicine cabinets. If approved, the drug would represent a significant achievement for Chinese pharmaceutical innovation on the global stage—a homegrown treatment developed independently rather than licensed from another country. For the millions of people worldwide who lie awake at night, the question now is how soon this option might become available.
Notable Quotes
As a fast-acting, short-half-life DORA, Fazamorexant can meet the treatment needs of patients with difficulty falling asleep while maintaining sleep without affecting daytime activities.— Professor Han Fang, Peking University People's Hospital
Emmanuel Mignot of Stanford University expressed interest in Fazamorexant and possible cooperation in further trials.— Emmanuel Mignot, Stanford University
The Hearth Conversation Another angle on the story
Why does it matter that this drug was developed in China rather than the United States or Europe?
Because for decades, the global pharmaceutical industry has been dominated by Western companies. When a Chinese firm develops an original drug that performs well enough to present at the world's top sleep medicine conference, it signals that innovation is shifting. It also means patients in Asia and elsewhere might get access to new treatments faster, without waiting for Western approval processes.
The trial compared Fazamorexant to other DORAs, but the source notes these comparisons come from different studies. Why is that important?
Because you can't directly compare results from two different trials—different patient populations, different dosing schedules, different measurement methods all affect outcomes. The company is being careful to note this, but the implication is still that their drug looks good. A head-to-head trial would be more definitive.
What's the practical difference between a drug that sedates you and one that blocks orexin?
Sedating drugs knock you out—they work but leave you groggy the next day. Orexin blockers work with your brain's natural sleep-wake system instead of against it. You fall asleep because the brain signals keeping you awake are muted, not because you've been chemically knocked down. That's why twice-nightly dosing becomes possible without daytime impairment.
The lack of rebound insomnia seems significant. Why?
Because it's a real problem with many sleep drugs. People take them for weeks, then stop, and suddenly they can't sleep at all—sometimes worse than before. They end up dependent. If Fazamorexant truly doesn't do this, it's a genuine safety advantage.
What happens next?
The company waits for China's drug regulator to review the application. If approved, it enters the market there first, probably. Then the question becomes whether it gets approved in the U.S., Europe, and elsewhere. Stanford's interest suggests Western researchers want to study it further, which could help with those approvals.